MiNK director receives stock grants as board pay

Holcomb John Bradley reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Holcomb John Bradley reported acquisition or exercise transactions in this Form 4 filing.

MiNK Therapeutics, Inc. director John Bradley Holcomb reported two stock-based compensation grants. On June 1, 2026, he received 1,091 shares of Common Stock as restricted stock units (RSUs) valued at $12.38 per share in lieu of cash board and committee retainers.

On March 2, 2026, he received an additional 1,239 RSU-based shares at $10.90 per share for Q1 2026 service. The filing notes these Q1 RSUs were not filed earlier due to an administrative error. After these awards, he directly holds 3,458 shares of MiNK Therapeutics common stock. The RSUs vest one month after each grant date, reflecting routine non-cash director compensation rather than open-market purchases.

Insider Trade Summary

Grant/Award: 2,330 shares

Grant/Award 2 txns

Insider Holcomb John Bradley

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	1,091	$12.38	$14K
Grant/Award	Common Stock	1,239	$10.90	$14K

Holdings After Transaction: Common Stock — 3,458 shares (Direct)

Footnotes (2)

1. F1. The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date.
2. F2. Due to an administrative error, the RSUs for Q1 2026 Board and committee compensation were not filed timely.

Key Figures

June 2026 RSU grant: 1,091 shares at $12.38/share March 2026 RSU grant: 1,239 shares at $10.90/share Total shares after grants: 3,458 shares +1 more

4 metrics

June 2026 RSU grant 1,091 shares at $12.38/share Grant on June 1, 2026 in lieu of cash retainers

March 2026 RSU grant 1,239 shares at $10.90/share Grant on March 2, 2026 for Q1 2026 board service

Total shares after grants 3,458 shares Direct holdings following reported transactions

Compensation grant count 2 acquisitions TransactionSummary acquireCount for RSU-related awards

Key Terms

restricted stock units ("RSUs"), contingent right, cash retainers, board and committee compensation

4 terms

restricted stock units ("RSUs") financial

"The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

contingent right financial

"RSUs, which represent a contingent right to receive one share of Common Stock"

cash retainers financial

"The RSUs were received in lieu of cash retainers for board and committee compensation"

board and committee compensation financial

"The RSUs were received in lieu of cash retainers for board and committee compensation"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did MiNK Therapeutics (INKT) director John Bradley Holcomb report in this Form 4?

He reported two stock-based compensation grants. The transactions reflect restricted stock units converted into common shares for board and committee service, rather than open-market buying, and increase his direct holdings in MiNK Therapeutics to 3,458 shares after the reported awards.

How many MiNK Therapeutics shares did Holcomb acquire through these grants?

He acquired 1,091 shares on June 1, 2026, and 1,239 shares on March 2, 2026. Both awards were made as restricted stock units for board and committee retainers, bringing his total direct holdings to 3,458 shares after these compensation-related transactions.

Were Holcomb’s MiNK Therapeutics transactions open-market purchases or compensation grants?

They were compensation grants, not open-market purchases. The filing classifies both as “Grant, award, or other acquisition,” with footnotes explaining that restricted stock units were issued instead of cash retainers for board and committee service, vesting one month after each grant date.

What prices were used to value John Bradley Holcomb’s MiNK Therapeutics RSU grants?

The June 1, 2026 grant used a value of $12.38 per share for 1,091 shares. The March 2, 2026 grant used $10.90 per share for 1,239 shares. These prices reflect the per-share values recorded for the restricted stock unit awards.

Why does the MiNK Therapeutics Form 4 mention an administrative error for Q1 2026 RSUs?

A footnote states that RSUs for Q1 2026 board and committee compensation were not filed on time due to an administrative error. The March 2, 2026 grant of 1,239 shares is therefore being reported now to correct the prior omission in regulatory reporting.

How do the MiNK Therapeutics RSUs granted to Holcomb vest?

The restricted stock units each convert into one share of common stock. According to the footnote, the RSUs vest one month from the grant date, meaning the director earns the underlying shares after a short service-based vesting period following each grant.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/02/2026 - 04:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Holcomb John Bradley

(Last) (First) (Middle)

149 FIFTH AVENUE, SUITE 500

(Street)

NEW YORK NEW YORK 10010

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MiNK Therapeutics, Inc. [ INKT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/02/2026		A		1,239	A	$10.9(2)	2,367	D
Common Stock	06/01/2026		A		1,091	A	$12.38(1)	3,458	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date.

2. Due to an administrative error, the RSUs for Q1 2026 Board and committee compensation were not filed timely.

	By: /s/ Melissa Orilall, Attorney-in-Fact	06/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)